Literature DB >> 12476614

Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors.

Iwona Lewy-Trenda1, Agnieszka Wierzchniewska-Ławska.   

Abstract

Vascular endothelial growth factor (VEGF) is one of the factors related to angiogenesis of tumors and physiological and pathological proliferative processes. Location of VEGF in human thyroid tissue with various thyroid disorders was studied in order to explore its possible involvement in proliferative processes. Immunohistochemical examination was performed on 69 formalin-fixed, paraffin-embedded thyroid tissue specimens using the labelled streptavidin biotin peroxidase complex detection system. VEGF was not identified in normal thyroid follicular cells. Some but not all tumor thyreocytes expressed VEGF in cytoplasm. VEGF positive expression was found in 6/15 patients with papillary carcinoma, 4/9 with follicular carcinoma, 14/28 with follicular adenoma and 2/17 with adenomatous goiter. In benign follicular adenoma and adenomatous goiter the weak expression of VEGF was found in small areas of the tumor tissues, whereas in malignant tumors it was found strongly in many cells. VEGF probably functions as a hypoxia-inducible angiogenic factor, and the expression of VEGF is stronger in malignant tumors, which need more oxygen supply to proliferate. An intensive VEGF production by differentiated thyroid carcinomas could be a promising marker of tumor aggressiveness and may also be useful as a predictor of metastatic potential and extension of tumor mass.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12476614

Source DB:  PubMed          Journal:  Pol J Pathol        ISSN: 1233-9687            Impact factor:   1.072


  5 in total

1.  Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS).

Authors:  Xi Wei; Ying Li; Sheng Zhang; Gao Ming
Journal:  Tumour Biol       Date:  2014-04-01

2.  [18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules.

Authors:  Elizabeth J de Koster; Adriana C H van Engen-van Grunsven; Johan Bussink; Cathelijne Frielink; Lioe-Fee de Geus-Oei; Benno Kusters; Hans Peters; Wim J G Oyen; Dennis Vriens
Journal:  Mol Imaging Biol       Date:  2022-10-17       Impact factor: 3.484

3.  The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.

Authors:  Joanna Klubo-Gwiezdzinska; Roman Junik; Ewa Kopczynska; Olga Juraniec; Hanna Kardymowicz
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

4.  Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma.

Authors:  Hai-Yan Zhang; Xin Meng; Zhen-Xian Du; Chang-Qing Fang; Guo-Liang Liu; Hua-Qin Wang; Wei-Wei Deng
Journal:  Clin Exp Med       Date:  2009-02-10       Impact factor: 3.984

Review 5.  Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications.

Authors:  Neel Rajan; Tilak Khanal; Matthew D Ringel
Journal:  Endocrine       Date:  2020-08-11       Impact factor: 3.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.